You are here

  • Home
  • Archive
  • Volume 12, Issue 3
  • Annual mammographic screening beginning at 40 years of age did not significantly reduce breast cancer mortality after 10 years in women

Article Text

Article menu
Download PDFPDF
Therapeutics
Annual mammographic screening beginning at 40 years of age did not significantly reduce breast cancer mortality after 10 years in women

https://doi.org/10.1136/ebm.12.3.71

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Moss SM, Cuckle H, Evans A, et al. Effect of mammographic screening from age 40 years on breast cancer mortality at 10 years’ follow-up: a randomised controlled trial. Lancet 2006;368:2053–60.
    OpenUrlCrossRefPubMedWeb of Science

    
 
 Q In women who are 40 years of age, does annual mammographic screening reduce breast cancer mortality after 10 years?

    Clinical impact ratings GP/FP/Primary care ★★★★★★☆ Gynaecology ★★★★★★☆ Oncology ★★★★★☆☆

    METHODS

    Embedded ImageDesign:

    randomised controlled trial (Age trial).

    Embedded ImageAllocation:

    concealed.*

    Embedded ImageBlinding:

    unblinded.*

    Embedded ImageFollow up period:

    mean 10.7 years.

    Embedded ImageSetting:

    23 National Health Service breast screening units in England, Wales, and Scotland.

    Embedded ImagePatients:

    160 921 women 39–41 years of age (mean age 40 y).

    Embedded ImageIntervention:

    women who were allocated to the intervention group (n = 53 914) were offered annual screening by mammography up to and including the calendar year of their 48th birthday. Women who were allocated to the control group (n = 107 007) received usual medical care.

    Embedded ImageOutcomes:

    breast cancer mortality and all cause mortality. …

    View Full Text

    Footnotes

    • ↵* See glossary.

    • For correspondence: Dr S Moss, Institute of Cancer Research, Sutton, UK. sue.moss{at}icr.ac.uk

    • Sources of funding: Medical Research Council and Cancer Research and US National Cancer Research Institute